Literature DB >> 15544019

Development and validation of the ORACLE score to predict risk of osteoporosis.

Florent Richy1, Fréderic Deceulaer, Olivier Ethgen, Olivier Bruyère, Jean-Yves Reginster.   

Abstract

OBJECTIVE: To develop and validate a composite index, the Osteoporosis Risk Assessment by Composite Linear Estimate (ORACLE), that includes risk factors and ultrasonometric outcomes to screen for osteoporosis. SUBJECTS AND METHODS: Two cohorts of postmenopausal women aged 45 years and older participated in the development (n = 407) and the validation (n = 202) of ORACLE. Their bone mineral density was determined by dual energy x-ray absorptiometry and quantitative ultrasonometry (QUS), and their historical and clinical risk factors were assessed (January to June 2003). Logistic regression analysis was used to select significant predictors of bone mineral density, whereas receiver operating characteristic (ROC) analysis was used to assess the discriminatory performance of ORACLE.
RESULTS: The final logistic regression model retained 4 biometric or historical variables and 1 ultrasonometric outcome. The ROC areas under the curves (AUCs) for ORACLE were 84% for the prediction of osteoporosis and 78% for low bone mass. A sensitivity of 90% corresponded to a specificity of 50% for identification of women at risk of developing osteoporosis. The corresponding positive and negative predictive values were 86% and 54%, respectively, in the development cohort. In the validation cohort, the AUCs for identification of osteoporosis and low bone mass were 81% and 76% for ORACLE, 69% and 64% for QUS T score, 71% and 68% for QUS ultrasonometric bone profile index, and 76% and 75% for Osteoporosis Self-assessment Tool, respectively. ORACLE had the best discriminatory performance in identifying osteoporosis compared with the other approaches (P < .05).
CONCLUSION: ORACLE exhibited the highest discriminatory properties compared with ultrasonography alone or other previously validated risk indices. It may be helpful to enhance the predictive value of QUS.

Entities:  

Mesh:

Year:  2004        PMID: 15544019     DOI: 10.4065/79.11.1402

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

Review 1.  Performance of the Osteoporosis Self-Assessment Tool in ruling out low bone mineral density in postmenopausal women: a systematic review.

Authors:  B Rud; J Hilden; L Hyldstrup; A Hróbjartsson
Journal:  Osteoporos Int       Date:  2007-03-15       Impact factor: 4.507

Review 2.  The Osteoporosis Self-Assessment Tool versus alternative tests for selecting postmenopausal women for bone mineral density assessment: a comparative systematic review of accuracy.

Authors:  B Rud; J Hilden; L Hyldstrup; A Hróbjartsson
Journal:  Osteoporos Int       Date:  2008-08-21       Impact factor: 4.507

3.  Development and validation of osteoporosis risk-assessment model for Korean postmenopausal women.

Authors:  Sun Min Oh; Byung-Ho Nam; Yumie Rhee; Seong-Hwan Moon; Deog Young Kim; Dae Ryong Kang; Hyeon Chang Kim
Journal:  J Bone Miner Metab       Date:  2013-02-19       Impact factor: 2.626

4.  Diagnostic value of osteoporosis self-assessment tool for Asians (OSTA) and quantitative bone ultrasound (QUS) in detecting high-risk populations for osteoporosis among elderly Chinese men.

Authors:  Xiao-Yun Zha; Yu Hu; Xiao-Na Pang; Gui-Lin Chang; Li Li
Journal:  J Bone Miner Metab       Date:  2014-04-20       Impact factor: 2.626

5.  An evaluation of osteoporosis screening tools for the osteoporotic fractures in men (MrOS) study.

Authors:  H S Lynn; J Woo; P C Leung; E L Barrett-Connor; M C Nevitt; J A Cauley; R A Adler; E S Orwoll
Journal:  Osteoporos Int       Date:  2008-02-01       Impact factor: 4.507

6.  Development and Validation of Osteoporosis Risk-Assessment Model for Korean Men.

Authors:  Sun Min Oh; Bo Mi Song; Byung Ho Nam; Yumie Rhee; Seong Hwan Moon; Deog Young Kim; Dae Ryong Kang; Hyeon Chang Kim
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.